Introducing IPC Pitch Judges at RESI JPM San Francisco

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

The Life Science Nation (LSN)‘s RESI JPM San Francisco 2023 is only less than two weeks away! For this conference, the Innovator’s Pitch Challenge (IPC) is especially popular and we are featuring over 50 presenting startups from across 14 sessions, each focusing on a specific sector/subsector. The LSN team has been very busy recruiting for active investors and industry experts to join the pitch judge panels. The investor and industry experts were invited to sessions based on their experience, investment interest and expertise. The judges will listen to 4-minutes of company pitches and have 8-9 minutes to engage in Q&A and provide feedback to the pitching companies.

Below is a partial list of IPC pitch judges at RESI San Francisco. Sign up for RESI SF 2023 to join them!


Brent Ahrens
General Partner
Canaan Partners

Ivneet Bhullar
Principal
Fusion Fund

Jian Cao
Sr Research Manager & Technical Fellow
Medtronic

Evan Caplan
Principal
OrbiMed Advisors LLC

Dipty Desai
Co-Chair, TiE Global Health
TiE Angels

Karen Drexler
Life Science Councils
Astia Angels

Gary Gershony
Partner
BayMed Venture Partners

Anton Gopka
CEO and General Partner
ATEM Capital

Linda Greub
General Partner
Avestria Ventures

Michael Hansen
Innovation Scouting Director – North America
Eppendorf

Dave Hood
West Coast Outreach
Medical Technology Enterprise Consortium (MTEC)

Melya Hughes Crameri
Managing Director
Awen GmbH

Tomoko Ishikura
Partner
Kicker Ventures

Elizabeth Kayser
Member
Barrington Angels

Moazam Khan
Business Advisor
Velocity Incubator

John Kim
Principal
Aphelion Capital, LLC

Kristin King
Member
Boston Harbor Angels

Bill Mantzoutsos
Angel Investor

Linda Maxwell
Director
Biomedical Zone

James Mayer
Senior Manager, Investment & Venture Services
Centre for Aging + Brain Health Innovation (CABHI)

Matthew McNamara
Chief Investment Officer
Horizon 3 Biotech

Brian Meshkin
Managing Partner
Profound Ventures

Ting Pau Oei
Venture Partner
Gore Range Capital

Daniel Parera
Partner
Kurma Partners

Diana Saraceni
Founder, Managing Director
Panakes Partners

Eran Steinberg
Imaging Arts

Lu Wang
Foothill Ventures

Kyoko Watanabe
Managing Director
DEFTA Partners

Tad Weems
Managing Director
Agilent Technologies

Travis Whitfill
Partner
Bios Partners

RESI-SF-2023-Banner-1100-wide

Partnering At RESI JPM San Francisco

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Partnering opened for RESI JPM San Francisco on December 19, and the RESI partnering platform is a hive of activity. The primary goal of RESI has always been to foster conversations between companies, investors and strategic partners, and service providers who can all work together to bring the next generation of healthcare technology to market. As a hybrid conference, we are seeing the number of meetings booked increase steadily. The hybrid format proves to be one that works for the RESI community, as we see meetings being scheduled for both the in-person conference and still seeing about half of the meetings so far scheduled virtually. For those who are still thinking of registering, there’s still time! You can still register for both in-person on Tuesday, January 10 at the Marines’ Memorial Club & Hotel (hurry, this is almost SOLD OUT), and Virtual January 11-12. In our experience, over 50% of the meetings are booked within the week before the conference, so there is still a lot of time left to book plenty of meetings!

RESI San Francisco is LSN’s largest event of the year – with over 400 investors already registered, and more registering every day, start the new year off right by catapulting your fundraising campaign forward with all the networking opportunities available at RESI and JPM.

RESI-SF-2023-Banner-1100-wide

Watershed Informatics Exhibit at RESI JPM San Francisco

Madeline-Kelly
Madeline Kelly
Interview with Madeline Kelly, Head of Sales, Watershed Informatics

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti
Caitlin Dolegowski

Watershed Informatics’ intuitive Data Lab platform empowers our clients to design, execute, and iterate their own sequencing analyses, shortening time between iterations and enabling more efficient and effective experimentation. They expedite and multiply the development of targeted, breakthrough therapies and diagnostics. Watershed returns to RESI this January as an exhibitor. In the following interview, Watershed’s Head of Sales, Madeline Kelly, provides insight on how Watershed came to be, their technology, team, and target customer.

Caiti Dolegowski (CD): Please introduce us to Watershed. Tell us about your technology and platform.

Madeline Kelly (MK): Watershed Informatics is the first fully verticalized bio-IT platform. Our Cloud Data Lab enables life sciences organizations of any size to perform mission-critical bioinformatics analyses (such as bulk, single-cell, and spatial transcriptomics; WGS, proteomics, protein folding, AI/ML etc.) at an order of magnitude less cost and complexity than existing solutions. With purpose-built infrastructure specifically optimized for catalyzing the life sciences development pipeline, our product enables biologists to analyze their own data and bioinformaticians to rapidly prototype and deploy bespoke analytic workflows across an organization.

CD: Tell us about Watershed’s team?

MK: We are a team of expert bioinformaticians, software engineers, and biologists inspired by one mission: to enable all scientists – regardless of their programming capabilities – to leverage multi-modal data for building better drugs faster.

CD: Watershed’s Cloud Data lab can be traced to a conversation between co-founders, Jonathan Wang and Mark Kalinich. What was the conversation and how do they complement each other?

MK: Jonathan and Mark have been friends since their first day of MIT – they were actually next-door neighbors freshman year! As a software engineer, Jonathan has always been fascinated by high-performance computational infrastructure. He co-founded an algorithmic trading firm while still a student at MIT. While there, he perfected the tech stack required to democratize access to petabyte-scale ML infrastructure for software engineers and financial researchers alike. Mark is a Harvard-trained physician-scientist with nearly 15 years of translational research experience across diagnostics and therapeutics development. His mission is to improve the lives of patients by developing and deploying the enabling technologies required to bring therapeutics out of the laboratory and into the clinic. Their expertise and passions directly intersect at the problem Watershed solves: uncorking the bottleneck for biotech and pharma’s data-intensive research efforts.

CD: Who is your target customer? And what are the different offerings you provide your clients?

MK: Our target customers want to successfully and efficiently analyze their big biology data (most often -omics, but also protein folding and high content imaging) without the massive overhead currently required. (To learn more about what we mean by overhead, download our white paper). With our no-code / low-code / high-code interoperability, our platform is useful to biologists and bioinformaticians alike.

CD: Do you have a process for assessing your clients’ needs? How does that work?

MK: Watershed employs a highly consultative sales and onboarding process. We thoroughly assess the needs of our customers by learning about their workflow, analysis, and visualization needs. Our team of bioinformaticians are ready to assist our clients from day 1.

CD: Could you give us examples of current Watershed clients and how they’ve utilized your informatics?

MK: Some of our clients include SalioGen, Cellino, SynDevRx, Rejuvenate Bio, Rarebase, Revitope, and a few stealth biotech startups. Our customers’ most common request is processing next-generation sequencing data across a variety of workflows (bulk, single-cell, and spatial RNAseq; whole genome and whole exome sequencing, bulk and single-cell ATACseq, immune repertoire sequencing, CRISPR-based analyses, custom sequencing libraries, etc) and technologies (Illumina, ONT, PacBio). In addition to other data-intensive workflows (metabolomics, proteomics, high-content imaging, protein-folding) and publicly available datasets (TCGA, CCLE, GTex, UKBB), our platform has been purpose-built to overlay advanced AI/ML techniques on these data, including deep learning, generative AI, structure-based learning models, and NLP, among others.

CD: We’re thrilled to Watershed back as an exhibitor at RESI JPM San Francisco! What would you like our RESI attendees to know about Watershed

MK: We are excited to join RESI JPM San Francisco as first-time attendees! We want to meet as many of you as possible, so swing by our booth to check out our platform and enter for a chance to win 1 free month of Watershed’s Cloud Data Lab (details available at the conference). See you there!

RESI-SF-2023-Banner-1100-wide

RESI JPM San Francisco 2023 Investor Panelists

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

RESI JPM San Francisco 2023 is fast approaching. The Life Science Nation (LSN) team has been busy putting together a program of 8 panels that provides latest insights on early-stage life science and healthcare.

We are excited to have invited a diverse lineup of panelists from different types of investment groups, including Big Pharma, corporate VCs, medtech strategics, traditional VCs, angels and family offices, to share their strategies and approaches on early-stage investment, perspectives on industry landscape, startup ecosystem and more. As a global conference, we are also delighted to have many international investors and cross-border investment groups to join and contribute to these dynamic discussions. The goal of RESI panels is to facilitate constructive conversations between investors and fundraising CEOs, and provide tactical advice on how companies can raise capital and acquire partnerships effectively. These must-see panels are great opportunities for founders and CEOs to engage with investors and kick off their fundraising journey of 2023.

Join the panelists below at RESI JPM San Francisco:


Mel Barsky
Director of Business Development
Centre for Aging + Brain Health Innovation (CABHI)

Lana Caron
Innovation Lead
Philips Ventures
Bruce Cohen
Bruce Cohen
Venture Partner
Xeraya Capital
Matt Deschner
Matt Deschner
Business Development & Licensing – Surgical Innovations
Medtronic

Gini Deshpande
Partner of Cathay Capital
Niels Emmerich
Niels Emmerich
Vice President, Global Head Search and Evaluation
AbbVie
Xi Fang
Xi Fang
Managing Partner
Button Capital
Jon Friedland
Jon Friedland
Managing Director, Ventures
Cleveland Clinic Ventures
Amit Garg
Amit Garg
Managing Partner
Tau Ventures
Lana Ghanem
Lana Ghanem
Managing Director
Hikma Ventures
Tom Gibbs
Tom Gibbs
Director
Debiopharm Innovation Fund
Gita Gupta
Gita Gupta
Partner
NextStep Ventures
Duncan Huston-Paterson
Duncan Huston-Paterson
Senior Manager, Business Development
Amgen
Kristin King
Kristin King
Member
Boston Harbor Angels
Fiona Mack
Fiona Mack
VP, Head of CoLaborator
Bayer
Nola Masterson
Nola Masterson
Managing Director
Science Futures
Andrew Meadow
Andrew Meadow
General Partner
Health Innovation Capital
Tamir Meiri
Tamir Meiri
Senior Manager, Venture Investments
Johnson & Johnson Innovation
Ole Mensching
Ole Mensching
Co-Founder and General Partner
Apollo Health Ventures
Ravi Mistry
Ravi Mistry
Angel Investor
John Parker
John Parker
Founder & Managing Director
Springhood Ventures
Armin Rump
Armin Rump
Manager, Global Business Development
Otsuka Pharmaceutical
Akhil Saklecha
Akhil Saklecha
Chief Scientific Officer, Acute Care
Danaher Corporation
Yoke Sin
Yoke Sin
Managing Partner
iGlobe Partners
Lesley Stolz
Lesley Stolz
Regional Vice President, Early Innovation Partnering
Johnson & Johnson Innovation
Sally Wang
Sally Wang
Venture Partner
Viva BioInnovator
Oscar Zhang
Oscar Zhang
Principal
Qiming Venture Partners
Lu Zhang
Lu Zhang
Managing Partner
Fusion Fund
Cheryl Zimberlin
Cheryl Zimberlin
Investment Director
M Ventures

RESI-SF-2023-Banner-1100-wide

Crafting the Perfect Message

By Karen Deyo, VP of Product, Israel BD, LSN

You’ve registered for a partnering conference.

You’ve filled out a profile in the partnering system detailing who you are and what your company does.

You’ve researched the investors in attendance and built a list of targets to book meetings with.

You hit “Request a Meeting” and freeze.

What message will increase your chances of the investor accepting the request?

Partnering is an involved process with multiple steps that must be taken to ensure optimal results. These steps often require major time investment, and we forget that, even after the hours we’ve poured into the process, none of it matters without a compelling message to pique the interest of a potential partner. Furthermore, this is a process that requires a plan for following up, since, as with any outreach, it will likely take more than one message to the investors to receive a response. These messages should be clear and concise, no more than a paragraph, highlighting your company and what makes it unique.

Life Science Nation (LSN) has developed and consolidated your partnering outreach into four separate messages:

  1. Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
  2. Company tagline (5-6 words explaining who you are and what you do)
  3. Elevator pitch (1-3 sentences describing the company and tech)
  4. Technology differentiation, product innovation, or market position
  5. Raise and milestone information
  6. Follow Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
  7. Follow Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on the business development? What makes your people special?
  8. Follow Up 3 (One Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later.

It should go without saying that the perfect message is meaningless without a well-researched and formulated target list and marketing collateral at the ready. Think of the perfect message like how an athlete approaches the arena on game day. It’s the starting shot of a long and exciting process. It won’t replace the training and conditioning that got you to game day, but it’ll ensure you’re off with a competitive edge.

Check Out the IPC Finalists Who Will Be Pitching at RESI JPM San Francisco 2023!

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

With about a month left until RESI JPM San Francisco, LSN is very excited to announce the list of finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC) at the upcoming RESI!

This round of IPC was the most popular one to date. With the increased interest, all the IPC slots were filled well before the initial application deadline.

Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition, the companies will be presenting a poster showcasing their technology in the exhibit hall.

Below are the participating companies – if you will be attending RESI, please be on the lookout for them. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 1,000 attendees expected to attend, you can register here!

RESI JPM San Francisco
Innovator’s Pitch Challenge Finalists

RESI-SF-2023-Banner-1100-wide

Global Tech Hub Gathering in San Francisco

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Tech hubs from around the world are coming to RESI in San Francisco! Tech hubs are a crucial part of the Life Science Nation (LSN) and RESI community as they provide capital, entrepreneurial support, lab space, and economic development for their cohort of aspiring scientist-entrepreneur and fundraising executives. With this immense support from tech hubs, their group of startups, who’ve raised less than $2M USD, can accelerate their entrepreneurship journey by participating in RESI at a discounted rate and taking advantage of LSN services. Ranging from universities, non-profits, incubators, accelerators, and regional and government organizations, they are all looking to connect with investors, strategic partners, and early-stage life science startups in San Francisco. Get to know these global communities of innovation!

Don’t see your organization on this list? Contact us to learn more about special offers for you and your startups!

RESI-SF-2023-Banner-1100-wide